{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:53:00Z","timestamp":1777452780298,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nevirapine 400 mg extended release tablets (nevirapine-XR) are a once-daily alternative to nevirapine 200 mg immediate release tablets (nevirapine-IR). Study objectives were to describe the effectiveness and tolerability of nevirapine-XR in clinical practice and, for patients who switched from once daily 2x200 mg nevirapine-IR to nevirapine-XR, compare virological suppression and plasma nevirapine concentrations during each treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HIV-1-infected adults entered the study cohort if they initiated nevirapine-XR in British Columbia (BC) Canada between 1 April 2012 and 30 September 2012 and were followed until 30 September 2013. Demographic and clinical variables were abstracted from the BC Centre for Excellence in HIV\/AIDS databases. Patients who switched from once daily nevirapine-IR to nevirapine-XR were monitored for 6 months pre- and post-switch with comparison of virological suppression (McNeamer's test) and median random plasma nevirapine concentrations (Wilcoxon\u2013Mann\u2013Whitney test) in each period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 536 nevirapine-XR-treated patients were 96% male, median (IQR) age 49.9 (44.0\u201356.9) years. Median follow-up was 15.6 (14.7\u201316.5) months, with 474\/536 (88%) maintaining virological suppression. Emergent drug resistance developed in 5\/536 (1%), adverse drug reactions in 17\/536 (3%) and, although 31\/536 (6%) reported \u2018whole\u2019 tablets in their stools, this was not associated with adverse outcomes. Among the 305 patients who switched from nevirapine-IR to nevirapine-XR, median (IQR) random plasma nevirapine concentration was higher during nevirapine-IR 5,000 (3,690\u20136,090) ng\/ml than nevirapine-XR 3,930 (3,050\u20135,150) ng\/ml ( P&lt;0.001), but there was no difference in virological suppression, 89% and 87% respectively ( P=0.414).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post-marketing study affirms the effectiveness and tolerability of nevirapine-XR as an alternative to nevirapine-IR in adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2908","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T05:31:12Z","timestamp":1431322272000},"page":"721-730","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada"],"prefix":"10.1177","volume":"20","author":[{"given":"Katherine J","family":"Lepik","sequence":"first","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"St Paul's Hospital \u2013 Pharmacy, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benita","family":"Yip","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A","family":"McGovern","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Ding","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Nohpal","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit E","family":"Watson","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junine","family":"Toy","sequence":"additional","affiliation":[{"name":"St Paul's Hospital \u2013 Pharmacy, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Akagi","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"},{"name":"St Paul's Hospital \u2013 Pharmacy, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P Richard","family":"Harrigan","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Moore","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S","family":"Hogg","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio SG","family":"Montaner","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Barrios","sequence":"additional","affiliation":[{"name":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"bibr1-IMP2908","unstructured":"Health Canada, Ottawa ON, Canada. Drug Product Database Online Query. (Product name: Viramune, Viramune XR). (Updated 25 February 2013. Accessed 24 December 2013.) Available from http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp\/index-eng.jsp."},{"key":"bibr2-IMP2908","unstructured":"US Food and Drug Administration, Silver Spring, MD, USA. Drugs@FDA, FDA approved drug products (drug name: Viramune, Viramune XR). (Updated 24 December 2013. Accessed 24 December 2013) Available from http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Search_Drug_Name."},{"key":"bibr3-IMP2908","unstructured":"World Health Organization, Geneva. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. (Updated 30 June 2013. Accessed 24 December 2013.) Available from http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/download\/en\/."},{"key":"bibr4-IMP2908","unstructured":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada. Antiretroviral (ARV) treatment of adult HIV infection. (Updated February 2013. Accessed 24 December 2013.) Available from http:\/\/cfenet.ubc.ca\/therapeutic-guidelines\/adult."},{"key":"bibr5-IMP2908","unstructured":"Department of Health and Human Services, Rockville, MD, USA. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 12 February 2013. Accessed 24 December 2013.) Available from http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"bibr6-IMP2908","unstructured":"Guidelines version 7.0 European AIDS Clinical Society, Brussels, Belgium. (Updated October 2013. Accessed 24 December 2013.) Available from http:\/\/www.eacsociety.org\/Guidelines.aspx."},{"key":"bibr7-IMP2908","volume-title":"Product monograph","author":"Viramune","year":"2013"},{"key":"bibr8-IMP2908","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00552.x"},{"key":"bibr9-IMP2908","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d3b54"},{"key":"bibr10-IMP2908","doi-asserted-by":"publisher","DOI":"10.1086\/528861"},{"key":"bibr11-IMP2908","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1418"},{"key":"bibr12-IMP2908","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00426.x"},{"key":"bibr13-IMP2908","doi-asserted-by":"publisher","DOI":"10.1310\/hct1102-110"},{"key":"bibr14-IMP2908","unstructured":"Rachel Therrien. A basic guide to antiretrovirals. 5th ed. Programme national de mentorat sur le VIH\/SIDA, Montreal QC, Canada. (Updated April 2008. Accessed 24 Dec 2013.) Available from http:\/\/www.hivmedicationguide.com\/pdf\/GuideARVs2008.pdf."},{"key":"bibr15-IMP2908","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15997-7"},{"key":"bibr16-IMP2908","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318198a0cc"},{"key":"bibr17-IMP2908","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1803"},{"key":"bibr18-IMP2908","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1468-1293.2011.00969.x","volume":"13","author":"Arasteh K.","year":"2012","journal-title":"HIV Med"},{"key":"bibr19-IMP2908","unstructured":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada. How to obtain HIV medication through the Drug Treatment Program. (Accessed 24 December 2013.) Available from http:\/\/www.cfenet.ubc.ca\/drug-treatment-program\/how-obtain-hiv-medication."},{"key":"bibr20-IMP2908","unstructured":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada. Patient information sheet for Drug Treatment Program participants. (Updated 2012. Accessed 29 September 2014.) Available from http:\/\/www.cfenet.ubc.ca\/sites\/default\/files\/uploads\/Patient%20Information%20Sheet.pdf."},{"key":"bibr21-IMP2908","unstructured":"BC Centre for Excellence in HIV\/AIDS, Vancouver, BC, Canada. Pharmacovigilance. (Accessed 24 December 2013.) Available from http:\/\/www.cfenet.ubc.ca\/hiv-drug-safety\/report-drug-reaction."},{"key":"bibr22-IMP2908","unstructured":"Canadian Patient Safety Institute, Edmonton, AB, Canada. British Columbia's HIV Patient Safety Initiative: population-based surveillance system to monitor antiretroviral-related adverse events. (Updated 27 February 2009. Accessed 24 December 2013.) Available from http:\/\/www.patientsafetyinstitute.ca\/English\/research\/cpsiResearchCompetitions\/2006\/Documents\/Barrios\/Report\/Barrios%20Full%20Report.pdf."},{"key":"bibr23-IMP2908","doi-asserted-by":"publisher","DOI":"10.1086\/427192"},{"key":"bibr24-IMP2908","unstructured":"Nevirapine X.R. (Viramune XR\n                      TM\n                      ) tablet remnants in stool. Safety alert no.4. BC Centre for Excellence in HIV\/ AIDS, Vancouver, BC, Canada. (Updated September 2012. Accessed 3 January 2014.) Available from http:\/\/www.cfenet.ubc.ca\/sites\/default\/files\/uploads\/BC-CfE_SafetyAlert_No4_2012_09.pdf."},{"key":"bibr25-IMP2908","volume-title":"Product monograph","author":"Viramune","year":"2011"},{"key":"bibr26-IMP2908","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819e721b"},{"key":"bibr27-IMP2908","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342060-00009"},{"key":"bibr28-IMP2908","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00003"},{"key":"bibr29-IMP2908","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4212\/cjhp.v62i6.849","volume":"62","author":"Higgins N.","year":"2009","journal-title":"Can J Hosp Pharm"},{"key":"bibr30-IMP2908","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E563"},{"key":"bibr31-IMP2908","doi-asserted-by":"publisher","DOI":"10.1310\/B5VU-FU5F-QNWC-UDCK"},{"key":"bibr32-IMP2908","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.145"},{"key":"bibr33-IMP2908","unstructured":"Gathe J., Bogner J.R., Santiago S. Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine\/tenofovir in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE).\n                      XVIII International AIDS Conference\n                      . 18\u201323 July 2010, Vienna, Austria. Abstract THLBB202."},{"key":"bibr34-IMP2908","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.630391"},{"key":"bibr35-IMP2908","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12090"},{"key":"bibr36-IMP2908","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612474681"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:20Z","timestamp":1777380740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.3851\/IMP2908"],"URL":"https:\/\/doi.org\/10.3851\/imp2908","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}